


NEW STUDY - The ENERGY Study:

The first potential treatment option being investigated for infants with Generalized Arterial Calcification of Infancy (GACI/ENPP1 Deficiency)



Study Design

The ENERGY Study, INZ701-104, is a Phase 1b, open-label study to assess the safety, tolerability, pharmacokinetics (PK), and pharmacodynamics (PD) of INZ-701 (enzyme replacement therapy) in infant subjects aged > 1 month to < 1 year with GACI (ENPP1 Deficiency).

Subjects with a confirmed molecular diagnosis of GACI are eligible to participate in this study if all other eligibility criteria are met.

The study will consist of up to a 60-day Screening Period, a 52-week Treatment Period with an extension.

Current and Future Sites

Children's Hospital of Philadelphia

Philadelphia, PA

Principal Investigator Dr. David Weber
WEBERD@chop.edu

Boston Children's Hospital

Boston, MA

Principal Investigator : Dr Christina Jacobsen
christina.jacobsen@childrens.harvard.edu

Nationwide Children's Hospital

Columbus, OH

Principal Investigator: Dr Kristen Truxal
kristen.truxal@nationwidechildrens.org

Rady Children's Hospital

San Diego, CA

Principal Investigator: Dr Nathaly Sweeney
NSweeney@rchsd.org

University of Utah

Salt Lake City, Utah

Principal Investigator: Dr Lorenzo Botto
Lorenzo.Botto@hsc.utah.edu

For additional information, please contact a study site or
Catherine Nester, Inozyme Pharma @ Catherine.nester@inozyme.com
or call 717-587-0845
